Home  »  Companies   »  Travere Therapeutics Inc Still Hasn’t Convin...

Travere Therapeutics Inc Still Hasn’t Convinced Analysts?

Travere Therapeutics Inc (NASDAQ:TVTX) price closed lower on Friday, November 17, dropping -2.66% below its previous close.

A look at the daily price movement shows that the last close reads $6.01, with intraday deals fluctuated between $5.75 and $6.21. The company’s 5Y monthly beta was ticking 0.55. Taking into account the 52-week price action we note that the stock hit a 52-week high of $23.18 and 52-week low of $5.25. The stock subtracted -17.02% on its value in the past month.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"


Travere Therapeutics Inc, which has a market valuation of $439.63 million, is expected to release its quarterly earnings report Nov 07, 2023. Analysts tracking TVTX have forecast the quarterly EPS to shrink by -1.22 per share this quarter, while the same analysts predict the annual EPS to hit -$1.56 for the year 2023 and up to -$3.77 for 2024. In this case, analysts estimate an annual EPS growth of 64.30% for the year and -141.70% for the next year.

On average, analysts have forecast the company’s revenue for the quarter will hit $41.21 million, with the likely lows of $36.29 million and highs of $54.4 million. The average estimate suggests sales growth for the quarter will likely fall by -26.20% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $194.34 million for the company’s annual revenue in 2023. Per this projection, the revenue is forecast to grow -8.30% below that which the company brought in 2023.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with 2 upward and no downward reviews. On the technical perspective front, indicators give TVTX a short term outlook of 100% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.

The overview shows that TVTX’s price is at present -10.65% off the SMA20 and -29.91% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 37.39, with weekly volatility standing at 6.99%. The indicator jumps to 7.22% when calculated based on the past 30 days. Travere Therapeutics Inc (NASDAQ:TVTX)’s beta value is holding at 0.52, while the average true range (ATR) indicator is currently reading 0.53.

An analysis of the Travere Therapeutics Inc (NASDAQ:TVTX) stock in terms of its daily trading volume indicates that the 3-month average is 1.80 million. However, this figure increases on the past 10-day timeline to an average of 2.0 million.

Current records show that the company has 75.15M in outstanding shares. The insiders’ percentage holdings are 4.85% of outstanding shares while the percentage share held by institutions stands at 107.47%. The stats also highlight that short interest as of Oct 30, 2023, stood at 8.81 million shares, which puts the short ratio at the time at 6.24. From this we can glean that short interest is 11.72% of company’s current outstanding shares. Notably, we see that shares short in October rose slightly given the previous month’s figure stood at 8.42 million. But the -72.18% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.